241 – 255 of 556
- show: 15
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
-
Mark
Longitudinal degeneration of the basal forebrain predicts subsequent dementia in Parkinson's disease
(
- Contribution to journal › Article
-
Mark
Pre-analytical protocol for measuring Alzheimer's disease biomarkers in fresh CSF
(
- Contribution to journal › Article
-
Mark
The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects
(
- Contribution to journal › Article
-
Mark
Differential expression of cerebrospinal fluid neuroinflammatory mediators depending on osteoarthritis pain phenotype
(
- Contribution to journal › Article
-
Mark
Patient-centered connectivity-based prediction of tau pathology spread in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease from Other Neurodegenerative Disorders
(
- Contribution to journal › Article
-
Mark
Biomarker profiling beyond amyloid and tau : cerebrospinal fluid markers, hippocampal atrophy, and memory change in cognitively unimpaired older adults
(
- Contribution to journal › Article
-
Mark
Derivation and utility of an Aβ-PET pathology accumulation index to estimate Aβ load
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid neurogranin in an inducible mouse model of neurodegeneration : A translatable marker of synaptic degeneration
(
- Contribution to journal › Article
-
Mark
Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Plasma P-tau181 in Alzheimer’s disease : relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia
(
- Contribution to journal › Article
-
Mark
Maximizing Safety in the Conduct of Alzheimer's Disease Fluid Biomarker Research in the Era of COVID-19
(
- Contribution to journal › Letter
-
Mark
Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia
(
- Contribution to journal › Article